Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)

Kaban, Kübra; Greiner, Sarah M.; Holzmayer, Samuel; Tandler, Claudia; Meyer, Sophie; Hinterleitner, Clemens; Salih, Helmut R.; Märklin, Melanie

doi:10.3390/diagnostics11112041

Cited by 3 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4-1BB L and 4-1BB were abnormally expressed in tumor cells in hematopoietic malignancies, and their interaction promotes tumor growth in cutaneous T-cell lymphoma (34). Overexpression of 4-1BB on leukemic cells was significantly related to poor prognosis (35). Antitumor activity was enhanced in 4-1BB-knockout mice (36).…”

Section: -1bb In Cancer Progressionmentioning

confidence: 99%

Targeting 4-1BB for tumor immunotherapy from bench to bedside

Wang

Ji²,

Jiao³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Immune dysfunction has been proposed as a factor that may contribute to disease progression. Emerging evidence suggests that immunotherapy aims to abolish cancer progression by modulating the balance of the tumor microenvironment. 4-1BB (also known as CD137 and TNFRS9), a member of tumor necrosis factor receptor superfamily, has been validated as an extremely attractive and promising target for immunotherapy due to the upregulated expression in the tumor environment and its involvement in tumor progression. More importantly, 4-1BB-based immunotherapy approaches have manifested powerful antitumor effects in clinical trials targeting 4-1BB alone or in combination with other immune checkpoints. In this review, we will summarize the structure and expression of 4-1BB and its ligand, discuss the role of 4-1BB in the microenvironment and tumor progression, and update the development of drugs targeting 4-1BB. The purpose of the review is to furnish a comprehensive overview of the potential of 4-1BB as an immunotherapeutic target and to discuss recent advances and prospects for 4-1BB in cancer therapy.

show abstract

Section: -1bb In Cancer Progressionmentioning

confidence: 99%

Targeting 4-1BB for tumor immunotherapy from bench to bedside

Wang

Ji²,

Jiao³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Recent advances of nucleic acid-based cancer biomarkers and biosensors

Zhao,

Xia,

et al. 2023

Coordination Chemistry Reviews

View full text Add to dashboard Cite

Uncovering the Expression Pattern of the Costimulatory Receptors ICOS, 4-1BB, and OX-40 in Exhausted Peripheral and Tumor-Infiltrating Natural Killer Cells from Patients with Cervical Cancer

Rojas-Diaz,

Solorzano-Ibarra,

Garcia-Barrientos

et al. 2024

IJMS

View full text Add to dashboard Cite

Cervical cancer (CC) poses a significant health burden, particularly in low- and middle-income countries. NK cells play a crucial role against CC; however, they can become exhausted and lose their cytotoxic capacity. This work explores the expression of costimulatory receptors (ICOS, 4-1BB, OX-40) in exhausted NK cells from CC patients. Peripheral blood and tumor biopsies were collected, and flow cytometry was used to evaluate the expression of costimulatory receptors in exhausted NK cells. There is an increase of peripheral exhausted NK cells (PD-1+TIGIT+) in CC patients; this subpopulation has a selectively increased expression of the costimulatory receptors ICOS and 4-1BB. An exhausted population is also highly increased in tumor-infiltrating NK cells, and it shows a dramatically increased expression of the costimulatory receptors ICOS (>15×) and 4-1BB (>10×) compared to peripheral NK cells. The exhausted cells, both in the periphery and in the tumor infiltrating lymphocytes (TILs), are also more likely than non-exhausted NK cell populations (PD-1−TIGIT−) to express these costimulatory receptors; increases ranging from 2.0× ICOS, 2.4× 4-1BB, and 2.6× OX-40 in CD56dim PBMCs to 1.5× ICOS, 5× 4-1BB, and 10× OX-40 in TILs were found. Our study demonstrates for the first time the increased expression of the costimulatory receptors ICOS, 4-1BB, and OX-40 in peripheral CD56dim, CD56bright, and tumor-infiltrating NK cells in CC. Targeting these receptors for stimulation could reverse exhaustion and be a promising immunotherapy strategy.

show abstract

Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)

Cited by 3 publications

References 51 publications

Targeting 4-1BB for tumor immunotherapy from bench to bedside

Targeting 4-1BB for tumor immunotherapy from bench to bedside

Recent advances of nucleic acid-based cancer biomarkers and biosensors

Uncovering the Expression Pattern of the Costimulatory Receptors ICOS, 4-1BB, and OX-40 in Exhausted Peripheral and Tumor-Infiltrating Natural Killer Cells from Patients with Cervical Cancer

Contact Info

Product

Resources

About